Ripple-AT Study.

V. Luther, S. Agarwal, A. Chow, M. Koa‐Wing, N. Cortez-Dias, L. Carpinteiro, J. de Sousa, R. Balasubramaniam, D. Farwell, S. Jamil-Copley, N. Srinivasan, H. Abbas, James Mason, N. Jones, G. Katritsis, P. Lim, N. Peters, N. Qureshi, Z. Whinnett, N. Linton, P. Kanagaratnam
{"title":"Ripple-AT Study.","authors":"V. Luther, S. Agarwal, A. Chow, M. Koa‐Wing, N. Cortez-Dias, L. Carpinteiro, J. de Sousa, R. Balasubramaniam, D. Farwell, S. Jamil-Copley, N. Srinivasan, H. Abbas, James Mason, N. Jones, G. Katritsis, P. Lim, N. Peters, N. Qureshi, Z. Whinnett, N. Linton, P. Kanagaratnam","doi":"10.1161/CIRCEP.118.007394","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nRipple mapping (RM) is an alternative approach to activation mapping of atrial tachycardia (AT) that avoids electrogram annotation. We tested whether RM is superior to conventional annotation based local activation time (LAT) mapping for AT diagnosis in a randomized and multicenter study.\n\n\nMETHODS\nPatients with AT were randomized to either RM or LAT mapping using the CARTO3v4 CONFIDENSE system. Operators determined the diagnosis using the assigned 3D mapping arm alone, before being permitted a single confirmatory entrainment manuever if needed. A planned ablation lesion set was defined. The primary end point was AT termination with delivery of the planned ablation lesion set. The inability to terminate AT with this first lesion set, the use of more than one entrainment manuever, or the need to crossover to the other mapping arm was defined as failure to achieve the primary end point.\n\n\nRESULTS\nOne hundred five patients from 7 centers were recruited with 22 patients excluded due to premature AT termination, noninducibility or left atrial appendage thrombus. Eighty-three patients (pts; RM=42, LAT=41) completed mapping and ablation within the 2 groups of similar characteristics (RM versus LAT: prior ablation or cardiac surgery n=35 [83%] versus n=35 [85%], P=0.80). The primary end point occurred in 38/42 pts (90%) in the RM group and 29/41pts (71%) in the LAT group (P=0.045). This was achieved without any entrainment in 31/42 pts (74%) with RM and 18/41 pts (44%) with LAT (P=0.01). Of those patients who failed to achieve the primary end point, AT termination was achieved in 9/12 pts (75%) in the LAT group following crossover to RM with entrainment, but 0/4 pts (0%) in the RM group crossing over to LAT mapping with entrainment (P=0.04).\n\n\nCONCLUSIONS\nRM is superior to LAT mapping on the CARTO3v4 CONFIDENSE system in guiding ablation to terminate AT with the first lesion set and with reduced entrainment to assist diagnosis.\n\n\nCLINICAL TRIALS REGISTRATION\nhttps://www.clinicaltrials.gov. Unique identifier: NCT02451995.","PeriodicalId":10167,"journal":{"name":"Circulation: Arrhythmia and Electrophysiology","volume":"57 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation: Arrhythmia and Electrophysiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1161/CIRCEP.118.007394","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

Abstract

BACKGROUND Ripple mapping (RM) is an alternative approach to activation mapping of atrial tachycardia (AT) that avoids electrogram annotation. We tested whether RM is superior to conventional annotation based local activation time (LAT) mapping for AT diagnosis in a randomized and multicenter study. METHODS Patients with AT were randomized to either RM or LAT mapping using the CARTO3v4 CONFIDENSE system. Operators determined the diagnosis using the assigned 3D mapping arm alone, before being permitted a single confirmatory entrainment manuever if needed. A planned ablation lesion set was defined. The primary end point was AT termination with delivery of the planned ablation lesion set. The inability to terminate AT with this first lesion set, the use of more than one entrainment manuever, or the need to crossover to the other mapping arm was defined as failure to achieve the primary end point. RESULTS One hundred five patients from 7 centers were recruited with 22 patients excluded due to premature AT termination, noninducibility or left atrial appendage thrombus. Eighty-three patients (pts; RM=42, LAT=41) completed mapping and ablation within the 2 groups of similar characteristics (RM versus LAT: prior ablation or cardiac surgery n=35 [83%] versus n=35 [85%], P=0.80). The primary end point occurred in 38/42 pts (90%) in the RM group and 29/41pts (71%) in the LAT group (P=0.045). This was achieved without any entrainment in 31/42 pts (74%) with RM and 18/41 pts (44%) with LAT (P=0.01). Of those patients who failed to achieve the primary end point, AT termination was achieved in 9/12 pts (75%) in the LAT group following crossover to RM with entrainment, but 0/4 pts (0%) in the RM group crossing over to LAT mapping with entrainment (P=0.04). CONCLUSIONS RM is superior to LAT mapping on the CARTO3v4 CONFIDENSE system in guiding ablation to terminate AT with the first lesion set and with reduced entrainment to assist diagnosis. CLINICAL TRIALS REGISTRATION https://www.clinicaltrials.gov. Unique identifier: NCT02451995.
Ripple-AT研究。
背景:滴波映射(RM)是一种替代心房心动过速(AT)激活映射的方法,避免了电图注释。我们在一项随机多中心研究中测试了RM是否优于传统的基于注释的局部激活时间(LAT)映射用于AT诊断。方法采用CARTO3v4 confidence系统对AT患者随机进行RM或LAT制图。操作人员仅使用指定的3D绘图臂确定诊断,然后在需要时允许进行单个确认夹带操作。确定计划消融病灶组。主要终点是AT终止和计划消融病灶组的交付。无法在第一个病变组终止AT,使用多个夹带手法,或需要切换到另一个测绘臂被定义为未能达到主要终点。结果共纳入7个中心的105例患者,其中22例因AT过早终止、不可诱导或左心耳血栓而被排除。83例患者;RM=42, LAT=41)在两组具有相似特征的患者中完成了定位和消融(RM vs LAT:既往消融或心脏手术n=35 [83%] vs n=35 [85%], P=0.80)。主要终点发生在RM组的38/42(90%)和LAT组的29/41 (71%)(P=0.045)。RM组的31/42分(74%)和LAT组的18/41分(44%)在没有任何干扰的情况下实现了这一目标(P=0.01)。在未能达到主要终点的患者中,LAT组中有9/12(75%)的患者在转入RM伴夹带后终止了AT,而RM组中有0/4(0%)的患者转入LAT伴夹带后终止了AT (P=0.04)。结论srm在引导消融以第一个病灶集终止AT、减少夹带辅助诊断方面优于在CARTO3v4 confense系统上的LAT定位。临床试验注册https://www.clinicaltrials.gov。唯一标识符:NCT02451995。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信